Life Insurance with Autoimmune Disease 2026: Underwriting, Rates and Carriers

Life insurance with autoimmune disease 2026 underwriting is far more attainable than most people with lupus, rheumatoid arthritis, Crohn’s disease, psoriasis or multiple sclerosis expect. A decade ago, an autoimmune diagnosis often ended the conversation before it started. Today, carriers have better data, better reinsurance capacity and more product tiers, so many applicants are approved at standard or mildly substandard rates — especially when their condition is stable and well controlled.

What has not changed is that autoimmune disease is not one risk. It is dozens of risks lumped under one label. Mild plaque psoriasis confined to the elbows carries a very different mortality profile than lupus with kidney involvement. That is why two people with the same diagnosis can receive offers that differ by 200% or more.

This guide walks through how underwriters actually evaluate autoimmune conditions in 2026, which conditions are easiest and hardest to insure, how steroids and biologics affect your offer, sample rate ranges by age, and what to do if fully underwritten coverage is not available to you.

Key Takeaways

• Diagnosis alone rarely causes a decline. Severity, organ involvement, flare frequency and medication burden drive the decision.
• Best-case outcomes are possible. Mild, stable, long-diagnosed conditions can sometimes earn Standard or even Standard Plus rates.
• Table ratings are common and negotiable. A Table 2 to Table 6 offer is typical for moderate autoimmune risk, and different carriers will grade you differently.
• Age at diagnosis matters. A diagnosis after age 40 with no complications is usually treated more favorably than a childhood or teenage diagnosis.
• There is always a fallback. Simplified issue and guaranteed issue final expense policies accept many applicants who cannot pass full underwriting.
• Never accept the first offer. Shopping your case across carriers is the single highest-value action you can take.

Why Autoimmune Disease Changes Life Insurance Underwriting

An autoimmune disease occurs when the immune system mistakenly attacks healthy tissue. That attack can be localized — skin, joints, the gut lining — or systemic, involving the kidneys, heart, lungs, blood vessels or nervous system. Underwriters care about that distinction because mortality risk tracks organ damage, not diagnosis labels.

Carriers build their pricing around statistical life expectancy. When they review an autoimmune file, they are essentially asking four questions:

1. How long has the condition been diagnosed, and has it been stable during that time?
2. Has the disease damaged or threatened any major organ system?
3. How aggressive is the current treatment, and how long has it been at that level?
4. Are there complications that historically shorten life expectancy, such as kidney disease, cardiovascular events, clotting disorders or infections requiring hospitalization?

A 38-year-old with psoriasis limited to the skin and no arthritis is generally viewed as close to a standard risk. A 38-year-old with lupus nephritis, two hospitalizations and high-dose prednisone is viewed very differently. Both have an autoimmune disease. Only one has a mortality profile that insurers can comfortably price near standard.

For context, overall US life expectancy trends shape every carrier’s pricing model, and the CDC life expectancy tables are one of the reference points actuaries use when building mortality assumptions.

Autoimmune disease also influences mortality through indirect pathways. Chronic inflammation is associated with accelerated atherosclerosis, higher rates of cardiovascular events and increased risk of serious infection. Some conditions, such as lupus, can cause kidney damage that shortens life expectancy if it progresses. Others, such as rheumatoid arthritis, can raise the risk of interstitial lung disease. Underwriters are trained to look for these secondary effects because they often matter more than the original diagnosis.

Age at diagnosis is another major lever. A person diagnosed after age 40 who has had mild symptoms for a decade is generally viewed more favorably than someone diagnosed in their teens whose disease has had decades to cause complications. Similarly, a diagnosis that has been stable for five years carries less weight than one that has been unstable or required multiple medication changes in the past 12 months.

Gender and pregnancy history can also enter the picture for certain conditions. Lupus, for example, is more common in women, and carriers may ask about pregnancy complications, preeclampsia or a history of blood clots, because those can signal more aggressive disease or antiphospholipid syndrome. These factors are not automatic declines, but they are part of the complete picture.

How Life Insurance with Autoimmune Disease 2026 Underwriting Works

Fully underwritten coverage in 2026 still follows a predictable path, even though carriers have automated parts of it.

1. Application and interview. You answer health questions, often followed by a brief phone interview that digs into dates, medications and symptoms.
2. Prescription and claims databases. Carriers check pharmacy records and the MIB database to confirm what you reported. Undisclosed medications are the most common reason applications get flagged.
3. Medical exam. A paramedical examiner typically collects blood, urine, height, weight, blood pressure and sometimes an EKG, depending on age and face amount.
4. Attending Physician Statement (APS). For most autoimmune files, the carrier orders records from your treating rheumatologist, gastroenterologist, dermatologist or neurologist. This is the document that decides your case.
5. Reinsurance review. Larger policies are reviewed by the reinsurer, which may impose a stricter rating than the primary carrier proposed.
6. Offer. You receive a rate class, a table rating, a flat extra, or a decline.

Two things consistently improve outcomes. First, your records should show a stable pattern — consistent medication, few or no flares, routine labs, no emergency visits. Second, your treating physician’s notes should describe the condition as controlled, in remission, or mild. Underwriters read physician language literally. “Stable” and “well controlled” help; “chronic, progressive” or “worsening” hurts.

Accelerated underwriting programs that skip the exam are usually a poor fit for autoimmune applicants because most of them screen out any history of autoimmune disease. If you want coverage without an exam, look instead at simplified issue products, which are discussed in our no medical exam life insurance guide.

Table ratings are the most common way carriers price autoimmune risk. A Table 1 rating means the applicant pays roughly 25% more than standard. Each additional table adds another 25% or so, so Table 4 is approximately 100% above standard. Some carriers use letter grades (A through H) or debits instead of tables. A flat extra is a separate charge per $1,000 of coverage, often $2.50 to $10 per $1,000, that can be temporary or permanent.

Rate classes are not standardized across the industry. One carrier’s Table 3 may be another carrier’s Table 5, and one may approve with a flat extra while another declines. This is why a single quote is almost meaningless for an autoimmune applicant.

Lupus and Rheumatoid Arthritis: What Underwriters Ask

Systemic lupus erythematosus (SLE) is one of the more difficult autoimmune diagnoses to insure, largely because it can involve the kidneys, heart, lungs, blood and central nervous system. Carriers typically want to see a diagnosis that is at least two to three years old, no kidney involvement (normal creatinine and no protein in the urine), no central nervous system involvement, no history of blood clots, and stable or decreasing medication.

Applicants with mild, stable SLE who take hydroxychloroquine alone or with low-dose steroids are sometimes approved at table ratings in the Table 2 to Table 6 range. Those with lupus nephritis, antiphospholipid syndrome or repeated hospitalizations are usually declined for fully underwritten coverage and redirected to final expense or guaranteed issue products.

Underwriters reviewing lupus will look closely at lab trends, not just a single result. A creatinine that has been stable for two years is reassuring. A creatinine that is rising, even slightly, may trigger a decline. They will also look for proteinuria, complement levels, anti-dsDNA antibodies and hospitalizations. A rheumatologist’s note that says “quiescent” or “no active organ involvement” is extremely valuable.

Rheumatoid arthritis (RA) is generally more insurable than lupus, especially the seronegative and mild forms. Underwriters look at:

• Age at diagnosis and number of years since diagnosis
• Number and severity of affected joints
• Whether you have had joint replacement or deformity
• Extra-articular involvement such as lung, eye or blood vessel complications
• Current medications, including methotrexate, biologics and steroid dose
• Occupational impact — whether you have stopped working

Mild RA with no disability and no steroid use can land near Standard or a light table rating. RA that has caused significant disability or is treated with high-dose prednisone typically pushes you into Table 4 or higher, or into a simplified issue product.

For RA, carriers also care about the number of joints involved and whether the disease is erosive. Erosions on X-ray suggest more aggressive disease. A history of joint replacement can lead to a higher rating because it may indicate long-standing inflammation and reduced mobility. On the other hand, someone with RA who has been on the same biologic for five years with no flares and no disability may look surprisingly good on paper.

Crohn’s Disease, Ulcerative Colitis and Psoriasis Underwriting

Crohn’s disease and ulcerative colitis are inflammatory bowel diseases that underwriters treat as a spectrum. The favorable profile is a diagnosis that is more than 12 to 24 months old, no surgeries in the past several years, no fistulas, strictures or bowel obstruction, and remission maintained on a stable medication regimen.

The unfavorable profile includes multiple bowel resections, chronic steroid dependence, frequent flares, malnutrition, or use of a high-risk biologic combination. In most states, carriers will consider mild-to-moderate Crohn’s at Standard through Table 4 rates. Severe or surgically complex cases often move to simplified issue.

Underwriters will ask about the number of bowel movements per day, whether you have ever been hospitalized for a flare, and whether you have taken prednisone in the past year. They may also review albumin and hemoglobin levels, because chronic inflammation can cause anemia and low protein. A stable colonoscopy report and a letter from your gastroenterologist confirming remission can make a meaningful difference.

Psoriasis is the friendliest of the major autoimmune conditions to insure when it is limited to the skin. Plaque psoriasis without arthritis and without systemic treatment is often approved at Standard or Preferred rates. The picture changes when psoriasis is:

• Accompanied by psoriatic arthritis, especially with joint damage
• Treated with methotrexate, cyclosporine or biologics for many years
• Associated with metabolic syndrome, cardiovascular disease or diabetes
• Present with erythrodermic or pustular forms, which carry higher risk

Psoriatic arthritis without deformity is usually insurable at table ratings. Severe psoriatic arthritis with disability or spinal involvement is often declined for full underwriting.

Psoriasis is also linked to an increased risk of cardiovascular disease, especially in severe cases. Underwriters may look at blood pressure, cholesterol and BMI as part of the overall risk picture. If your psoriasis is mild but your cardiovascular markers are poor, the cardiovascular markers may drive the final rating more than the skin condition.

Multiple Sclerosis (MS) and Life Insurance

MS underwriting is the most carrier-dependent of all the conditions covered here. Some insurers decline any history of MS. Others will consider relapsing-remitting MS when specific conditions are met: a diagnosis older than two to three years, few or no relapses in recent years, no progression to secondary progressive MS, no significant mobility impairment, and no disabling cognitive symptoms.

Even in the best case, expect a substandard rating. Table 4 to Table 10 offers are realistic for stable relapsing-remitting MS, and some carriers add a flat extra that declines or disappears after a set number of years. If you use a wheelchair, walker or require daily assistance, fully underwritten coverage is generally not available, and the practical route is guaranteed issue final expense coverage.

Because MS outcomes vary so widely by carrier appetite, this is the condition where getting multiple quotes matters most. A single agent with one carrier relationship is a bad fit for an MS case.

Carriers will want to know the date of your last relapse, the date of your last MRI, whether there are new or enhancing lesions, and whether you have any bowel or bladder symptoms. They will also look at your medication history. Older injectable therapies such as interferon may be viewed differently than newer infusions, but the key question is always stability: how long since the last attack, and how much function has been lost.

Carrier Tolerance Table for Common Autoimmune Conditions

The table below summarizes typical 2026 market patterns for fully underwritten coverage. It is illustrative, not a promise — every carrier evaluates your complete file, and your result depends on your specific history.

Rate classes shift with age, tobacco use and other health conditions. Two applicants with identical autoimmune histories can be graded four table steps apart by different carriers, which is exactly why comparing offers is worth the effort.

Medications, Steroids and Biologics: What Underwriters Weigh

Medication tells the underwriter how serious your disease is and how well it is controlled. The same drug can help or hurt depending on dose and duration.

• Hydroxychloroquine, sulfasalazine, mesalamine. Generally viewed favorably. These suggest mild disease managed without immunosuppression.
• Methotrexate. Common and usually acceptable. Long-term use at higher doses raises questions about liver function, so expect carriers to review liver enzyme results.
• Biologics (adalimumab, etanercept, infliximab, ustekinumab and similar). Not disqualifying on their own. A biologic that has kept you stable for years with no hospitalizations often looks better than uncontrolled disease on no treatment. Carriers may still apply a table rating because biologic use signals moderate-to-severe disease.
• Oral steroids (prednisone). The single biggest medication concern. Daily prednisone above roughly 10 mg, or long-term use at any dose, raises risk because of cumulative effects: diabetes, osteoporosis, infections, cardiovascular strain and weight gain. Tapering to a lower dose before you apply can measurably improve your offer.
• Immunosuppressants (azathioprine, cyclosporine, tacrolimus). Usually indicate more significant disease activity. Often insurable, but typically at higher table ratings.
• Opioids or chronic pain management. Can complicate an autoimmune file even when the autoimmune disease itself is well controlled.

Do not stop or change a prescribed medication to improve an insurance offer.

Frequently Asked Questions

Can I get life insurance with an autoimmune disease in 2026?

Yes, many US carriers offer coverage for autoimmune conditions like rheumatoid arthritis, lupus, and Crohn’s, though approval and rates depend on severity, treatment, and control. In 2026, accelerated underwriting and improved data analytics have expanded options for well-managed cases.

How does underwriting work for autoimmune disease life insurance in 2026?

Underwriters review your specific diagnosis, age at onset, frequency of flares, medications (especially biologics or steroids), and recent lab results. They also check for complications like organ involvement or secondary conditions, which can impact your risk class.

Which life insurance carriers are best for autoimmune diseases in 2026?

Carriers like Prudential, Mutual of Omaha, and Lincoln Financial are often cited for competitive rates on well-controlled autoimmune conditions, while some specialize in impaired-risk cases. Working with an independent agent who knows 2026 underwriting guidelines can help you find the most lenient carrier.

How much more will I pay for life insurance with an autoimmune disease?

You may pay 20% to 200% more than standard rates, depending on the disease and severity; mild, well-controlled conditions might qualify for standard or slightly substandard rates. Severe or unstable cases may face table ratings or declined offers.

Can I get no-exam life insurance with an autoimmune disease in 2026?

Some simplified issue or accelerated underwriting policies don’t require a medical exam, but they still ask health questions and may order prescription and medical records. If your autoimmune disease is severe or unstable, you may need a fully underwritten policy for the best chance of approval.

What can I do to improve my chances of approval and lower rates?

Maintain consistent treatment, keep flares minimal, and provide detailed medical records showing stability and good lab results. Quitting smoking, managing weight, and documenting a history of adherence to your specialist’s plan can also help.

What if my autoimmune disease is in remission or well-controlled?

Many carriers offer better rates for remission—typically defined as no flares or medication changes for 6 to 12 months—and may even consider standard rates for conditions like Hashimoto’s or psoriasis. In 2026, some insurers use remission periods as a key factor for preferred classes.

Related Reading

Keep researching before you apply:

• Life Insurance with an Autoimmune Disease 2026: Underwriting, Rates an
• Life Insurance Basics 2026: Terms, Coverage Types and How to Choose
• Life Insurance vs Annuity 2026: Which Does Your Family Actually Need?

Underwriting and medical background information in this guide was checked against authoritative sources, including Autoimmune Diseases. Autoimmune Disease.

Nerve-pain conditions are addressed separately in our guide to life insurance with trigeminal neuralgia.